Product Information
BARACLUDE 0.5 MG TABLET is a brand product labeled by E.R. Squibb & Sons, L.L.C., priced at $44.1865 per EA under NDC 00003161112. Its NADAC has been published 345 times since Nov 28, 2013.
FDA first approved this application on Mar 29, 2005. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the entecavir market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
.5 mg/1
Manufacturer
E.R. Squibb & Sons, L.L.C.NDC
00003161112
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
11/19/2025
Active Ingredients
ENTECAVIRApproval Type
New Drug (NDA)
FDA Application
NDA021797FDA Approved
3/29/2005
TE Code
AB
On Market Since
3/29/2005
Pharmacological Classes
Price Statistics
The NADAC for BARACLUDE 0.5 MG TABLET has been published 345 times since Nov 28, 2013, and over the history we have for it it has risen 31.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $44.1865 per EA |
|---|---|
| All-time high | $44.2907 (Oct 16, 2024) |
| All-time low | $33.6080 (Nov 28, 2013) |
| 52-week high | $44.1865 |
| 52-week low | $44.1200 |
| Median price | $44.0898 |
| Average price | $42.0211 |
| Largest weekly change | +12.0% (Jan 8, 2014) |
| Weeks tracked | 345 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the entecavir market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
E.R. Squibb & Sons, L.L.C. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
entecavir market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BARACLUDE 0.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for BARACLUDE 0.5 MG TABLET, manufactured by E.R. Squibb & Sons, L.L.C., is $44.1865 per EA (NDC 00003161112), effective Sep 30, 2026.
How has the price of BARACLUDE 0.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for BARACLUDE 0.5 MG TABLET has risen 31.5%. It has been tracked across 345 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for BARACLUDE 0.5 MG TABLET?
Since Nov 28, 2013, the NADAC for BARACLUDE 0.5 MG TABLET has ranged from a low of $33.6080 (Nov 28, 2013) to a high of $44.2907 (Oct 16, 2024), with a median of $44.0898 per EA.
Are there cheaper alternatives to BARACLUDE 0.5 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of BARACLUDE 0.5 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures BARACLUDE 0.5 MG TABLET?
BARACLUDE 0.5 MG TABLET (NDC 00003161112) is labeled by E.R. Squibb & Sons, L.L.C., and CMS classifies it as a brand product.